Market Size of United Arab Emirates Drug Delivery Devices Industry
| Study Period | 2021 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Historical Data Period | 2021 - 2022 |
| CAGR | 20.00 % |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
UAE Drug Delivery Devices Market Analysis
The UAE drug delivery devices market is poised to register a CAGR of 20% over the forecast period.
COVID-19 has significantly impacted the growth of drug delivery devices in the United Arab Emirates. Due to the increased infection among the population, the demand for vaccines has increased, which has fueled the demand for drug-delivery devices in the country. For instance, from an article published in Nature Immunology in July 2021, it has been observed that in cooperation with international organizations, the Abu Dhabi Medical Devices Company delivered more than 500 million syringes and needles for COVID-19 vaccinations, which was equal to 25% of UNICEF and COVAX's projected global need for 2021. Moreover, with the released COVID-19 restrictions, resumed services and treatment procedures as well as increased patient visits, the demand for drug delivery devices for administering drugs is expected to increase over the forecast period. This, in turn, is anticipated to fuel market growth.
Certain factors that are propelling the market growth are the increased prevalence of chronic diseases, technological advancements, rising individual therapy, the growing understanding of drug metabolism among the population, and the requirement for controlled drug release.
As drug delivery devices help deliver drugs, which are beneficial for the targeted population to recover faster, there has been a growing adoption and inclination toward advanced drug delivery devices. Moreover, the increasing number of cancers, respiratory diseases, and diabetic patients across the world may promote the adoption of drug-delivery devices and drive the overall market. For instance, as per the GLOBOCAN 2020 factsheet, 4,807 new cancer cases were reported in 2020 in the United Arab Emirates, while the five-year prevalence (all ages) was 14,816. In addition, as per the same source, 1,030 new cases of breast cancer, 405 of thyroid cancer, 334 colon cancer, 270 prostate cancer, 226 lung cancer, and 164 rectum cancer were reported in 2020 in the United Arab Emirates. Also, the highest prevalence of cancer was found in women (2,652) compared to men (2,155). This growing burden of cancer increases the adoption of drug-delivery devices, which is expected to contribute significantly to market growth over the forecast period.
In addition, according to the 2022 statistics published by the IDF, in the United Arab Emirates, 0.99 million people were living with diabetes in 2021. In addition, as per the same source, this number is projected to reach 1.17 million by 2030 and 1.32 million by 2045. Thus, the increase in the number of people suffering from diabetes is expected to fuel the demand for novel drug delivery devices, which, in turn, is anticipated to propel market growth over the forecast period.
Similarly, according to an article published in the World Journal of Gastroenterology in July 2020, about 372,000 people were projected to develop the non-alcoholic fatty liver disease (NAFLD) in the United Arab Emirates by 2030. In addition, as per the same source, the prevalence of NAFLD was expected to rise by 87% by 2030 in the United Arab Emirates. Thus, the increase in the population suffering from NAFLD is expected to increase the demand for nanocarrier drug delivery system that delivers the drug to specific liver cell types that help in improving efficacy and reducing side effects. This is anticipated to fuel the growth of drug delivery devices in the country over the forecast period.
Furthermore, as per a meta-analysis study published in December 2021, it has been observed that the combined prevalence of hypertension was 31% in the United Arab Emirates. In addition, as per the same source, the prevalence of hypertension was highest in Dubai (37%) than in the Abu Dhabi region (29%). Thus, the elevated blood pressure in the population causes the left ventricle to thicken, which increases the risk of heart attack, and cardiac failure. This is expected to increase the demand for conventional and advanced drug delivery devices, thereby propelling market growth.
However, the risk of needlestick injuries is likely to hinder the market growth over the forecast period.
UAE Drug Delivery Devices Industry Segmentation
As per the scope, drug delivery devices or systems are the tools used to deliver the drug through the specific route of administration. It enables the introduction of therapeutic substances into the body.
The UAE drug delivery devices market is segmented by Mode of Delivery (Nasal, Oral, Injectable, Transdermal, Topical, and Other Modes of Delivery). The report offers the value (in USD million) for the above segments.
| By Mode of Delivery | |
| Nasal | |
| Oral | |
| Injectable | |
| Transdermal | |
| Topical | |
| Others (Pulmonary, Rectal, Occular, Implantable) |
United Arab Emirates Drug Delivery Devices Market Size Summary
The United Arab Emirates drug delivery devices market is experiencing significant growth, driven by various factors including the increased prevalence of chronic diseases, technological advancements, and the rising demand for targeted therapies. The market is expected to expand rapidly over the forecast period, with a notable impact from the COVID-19 pandemic, which heightened the demand for vaccines and, consequently, drug delivery devices. The resumption of services and treatment procedures post-pandemic has further fueled the demand for these devices. The growing understanding of drug metabolism and the need for controlled drug release are also contributing to the market's expansion. The increasing incidence of cancers, respiratory diseases, and diabetes is promoting the adoption of advanced drug delivery systems, which are essential for effective treatment and recovery.
The market is characterized by a competitive landscape with several major players, including Becton, Dickinson and Company, GlaxoSmithKline PLC, Merck KGaA, and Bayer AG. The oral and injectable drug delivery segments are anticipated to witness substantial growth due to their flexibility, reduced dosing frequency, and better patient compliance. The rising adult and aging population in the UAE, coupled with the increasing drug approvals and company activities in developing injectable drugs, is expected to drive market growth. Additionally, partnerships and acquisitions, such as those by Abu Dhabi Medical Devices Company and ADQ, are enhancing the UAE's capability to manufacture medical equipment locally, further supporting market expansion. Despite the promising growth prospects, challenges such as the risk of needlestick injuries may pose hurdles to market development.
United Arab Emirates Drug Delivery Devices Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Rising Prevalence of Chronic Diseases and Growth in the Biologics Market
-
1.2.2 Increased Understanding of Drug Metabolism and Growing Requirement of Controlled Drug Release and Technological Advancements
-
-
1.3 Market Restraints
-
1.3.1 High Cost of Development, Regulatory Concern and Risk of Needlestick Injuries
-
-
1.4 Porter's Five Force Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION (Market Size by Value - USD million)
-
2.1 By Mode of Delivery
-
2.1.1 Nasal
-
2.1.2 Oral
-
2.1.3 Injectable
-
2.1.4 Transdermal
-
2.1.5 Topical
-
2.1.6 Others (Pulmonary, Rectal, Occular, Implantable)
-
-
United Arab Emirates Drug Delivery Devices Market Size FAQs
What is the current United Arab Emirates Drug Delivery Devices Market size?
The United Arab Emirates Drug Delivery Devices Market is projected to register a CAGR of 20% during the forecast period (2024-2029)
Who are the key players in United Arab Emirates Drug Delivery Devices Market?
AstraZeneca PLC, Bayer AG, Merck KGaA, GlaxoSmithKline PLC and Becton, Dickinson and Company are the major companies operating in the United Arab Emirates Drug Delivery Devices Market.
